Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase NA × Thalassemia × Cyclophosphamide × Clear all

Phase

Phase 2 2 Phase NA 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 24 Breast Neoplasms 23 Leukemia 21 Precursor Cell Lymphoblastic Leukemia-Lymphoma 20 Lymphoma, Non-Hodgkin 20 Multiple Myeloma 17 Lymphoma, Large B-Cell, Diffuse 16 Leukemia, Myeloid, Acute 15 Hodgkin Disease 15 Myelodysplastic Syndromes 14 Lymphoma, Mantle-Cell 14 Lymphoma, Follicular 14 Leukemia, Lymphocytic, Chronic, B-Cell 13 Myeloproliferative Disorders 10 Lymphoma, B-Cell, Marginal Zone 10 Congenital Abnormalities 10 Burkitt Lymphoma 10 Primary Myelofibrosis 9 Lymphoma, Large-Cell, Immunoblastic 9 Leukemia, Myeloid, Chronic-Phase 9 Leukemia, Myeloid, Accelerated Phase 9 Lymphoma, T-Cell, Cutaneous 8 Blast Crisis 8 Neoplasms, Plasma Cell 7 Dendritic Cell Sarcoma, Interdigitating 7 Sezary Syndrome 6 Recurrence 6 Myelodysplastic-Myeloproliferative Diseases 6 Mycosis Fungoides 6 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 6

Interventions

fludarabine phosphate 1 fludarabine 1 Mesna 1 Cyclophosphamide 1 Busulfan 1 Alemtuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00578292 2020-05-01

THALLO

Baylor College of Medicine

Phase NA Terminated

10 enrolled 15 charts

Lymphoma, Follicular, Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡